Webinar Series: Beyond the Black Box: Understanding Cardiovascular Risk with JAK Inhibitors

JAK inhibitors have transformed the treatment of inflammatory skin disease but have also raised concerns regarding cardiovascular and thrombotic risk. This 60-minute webinar will review the biologic basis of JAK inhibition, examines the evidence that led to current FDA boxed warnings, and provides a practical approach to cardiovascular risk assessment and patient counseling in everyday dermatology practice.

Participants will:

1. Review immune pathways and their relevance to major adverse cardiac events (MACE) and venous thromboembolism (VTE) risk
2. Explain the evidence and rationale underlying the FDA boxed warning for JAK inhibitors.
3. Evaluate available data regarding cardiovascular safety outcomes among JAK inhibitors and related immunomodulatory therapies used in dermatology.
4. Recognize clinical scenarios in which further cardiovascular evaluation or consultation may be appropriate in the development of shared decision-making with patients.

This activity has been reviewed by the American Academy of Physician Associates Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid from 7/24/2026 to 7/23/2027. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-2016065.